Impact of the 23-valent pneumococcal polysaccharide vaccination in pregnancy against infant acute lower respiratory infections in the Northern Territory of Australia

Similar Items

• Repeat pneumococcal polysaccharide vaccination does not impair functional immune responses among Indigenous Australians
  od: Licciardi, Paul V, i dr.
  Izdano: (2017)
• Serotype-specific avidity is achieved following a single dose of the 7-valent pneumococcal conjugate vaccine, and is enhanced by 23-valent pneumococcal polysaccharide booster at 12 months
  od: Russell, FM, i dr.
  Izdano: (2011)
• Safety and Immunogenicity of the 23-Valent Pneumococcal Polysaccharide Vaccine at 12 months of age, following One, Two, or Threes Doses of the 7-valent Pneumococcal Conjugate Vaccine in Infancy
  od: Russell, F.M., i dr.
  Izdano: (2010)
• Opsonophagocytic Activity Following a Reduced Dose 7-valent Pneumococcal Conjugate Vaccine Infant Primary Series and 23-valent Pneumococcal Polysaccharide Vaccine at 12 Months of Age
  od: Russell, FM, i dr.
  Izdano: (2010)
• Emerging pneumococcal carriage serotypes in a high-risk population receiving universal 7-valent pneumococcal conjugate vaccine and 23-valent polysaccharide vaccine since 2001
  od: Leach, Amanda J, i dr.
  Izdano: (2009)